Awarded
Blood product required for the treatment of TTP patients
£97,500
goods
Contract Details
- Stage
- Awarded
- Published
- Awarded
Timeline
Start
Awarded
Disclosed
End
Description
Octaplas, blood product required for the treatment of TTP patients. CMU National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B Offer reference number: CM/PHS/19/5576
Related Contracts
From This Buyer
- ANTT Safety Cannulation Procedure Packs
£5,272,175 ·
- Clinical Coding Consultancy Services
£480,000 ·
- IT Peripherals Managed Catalogue
£950,000 ·
- Diagnostic Testing
£4,798,391 ·
From This Supplier
- Octapharma - Blood Disorder Treatment products (inc Haemophilia A & B)
£71,550 ·
- Octapharma Ltd - Octaplas LG
£52,500 ·
- Octaplex Treatment
£100,000 ·
- Human Normal Immunoglobulin and Anti-D Immunoglobulin
£450,000,000 ·
In This Category
- ITSM Tool 26+
£125,900 ·
- Supply of Targeted Cell Lineage Separation
£484,494 ·
- NCC1706 Vulnerability Management System
£34,853 ·
- NCC1934 Telecare Equipment Purchase
£316,000 ·
Ref: 1c3e34fb-ff9b-43bb-9849-8acce6ae1cbe-560150 · Sourced from Contracts Finder
View source notice